NCT00178919 is a NA clinical trial of L-NMMA in Hypertension, sponsored by Vanderbilt University.

Who is sponsoring NCT00178919?

NCT00178919 is sponsored by Vanderbilt University.

What drugs are being tested in NCT00178919?

Interventions in NCT00178919: L-NMMA, Trimethaphan.

What condition does NCT00178919 study?

NCT00178919 studies Hypertension, Pure Autonomic Failure.

Is NCT00178919 still recruiting?

NCT00178919 is currently completed. Last updated 24 May 2013.

Are results published for NCT00178919?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2013-05-24 · How we verify

NCT00178919

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiovascular Regulation: Autonomic/Metabolic Mechanisms PO1 HL56693, Project 4: Cardiovascular Regulation: Autonomic/Metabolic Mechanisms

Completed NA Results posted Last updated 24 May 2013

What this trial tests

NA trial testing L-NMMA in Hypertension in 112 participants. Completed in 1 August 2008.

Timeline

1 August 2002

Primary endpoint
1 August 2008

1 August 2008

Quick facts

Lead sponsor	Vanderbilt University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Enrollment	112
Start date	1 August 2002
Primary completion	1 August 2008
Estimated completion	1 August 2008
Sites	1 location across United States

Drugs / interventions tested

L-NMMA — full drug profile →
Trimethaphan — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →
Pure Autonomic Failure — all drugs for Pure Autonomic Failure →

Sponsor

Vanderbilt University

Who can join

Adults 18 to 85, any sex, with Hypertension or Pure Autonomic Failure. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in Systolic Blood Pressure
Time frame: At the end of the highest tolerated dose of IV infusion of L-NMMA
L-NMMA (nitric oxide synthase inhibitor) was infused intravenously at different doses for 15 minutes each, after blocking the autonomic nervous system with trimethaphan. The change in systolic blood pressure at the end of the highest tolerated dose is the main outcome. Trimethaphan infused intravenously was used to produce transient blockade of the autonomic nervous system to allow for a full resp
Systolic Blood Pressure in Response to Systemic Nitric Oxide Inhibition
Time frame: End of 15 minutes of infusion of L-NMMA at the highest tolerated dose
Systolic blood pressure at the highest tolerated dose of IV infusion of L-NMMA during autonomic nervous system blockade with trimethaphan. Trimethaphan, infused intravenously was used to produce transient blockade of the autonomic nervous system to allow for a full response to nitric oxide inhibition (in the absence of the baroreflex.

Sponsor's own description

The amount of blood flowing to the different parts of the body is regulated by the autonomic (automatic) nerves and by local factors produced by the blood vessels. Nitric oxide (NO) is one of the most important of these metabolic factors. If the production of NO is slowed or stopped the amount of blood to the different parts of the body is decreased. There is increasing knowledge that NO mechanisms are impaired in a number of medical conditions. NO function is reduced in patients with risk factors for atherosclerosis (hardening of the arteries) such as hypercholesterolemia (patients with high cholesterol), or diabetes mellitus, and is also impaired in smokers. This NO "deficiency" is believed to contribute to the greater cardiovascular risk that marks these patient populations. This study is designed to examine if endothelial nitric oxide is an important control mechanism of blood pressure under normal conditions, and if impairment of nitric oxide contributes to hypertension.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure.
Gamboa A, Shibao C, Diedrich A, Paranjape SY, et al · · 2008 · cited 47× · PMID 18426998 · DOI 10.1161/hypertensionaha.107.105171

Verify or expand the search:

Other trials of L-NMMA

Trials testing the same drug.

NCT05660083 — Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) · Phase 2 · recruiting
NCT03066115 — Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation · Phase 1 · withdrawn
NCT03236935 — Phase Ib of L-NMMA and Pembrolizumab · Phase 1 · completed
NCT00508989 — Niacin to Improve Blood Flow in People With Sickle Cell Disease · Phase 2 · completed
NCT00327080 — Sildenafil to Treat HIV-Associated Pulmonary Hypertension · Phase 1 · terminated

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Vanderbilt University trials

Trials by the same sponsor.

NCT06598579 — Evaluation of MBCT Implemented in Vietnamese Buddhist Pagoda · NA · not yet recruiting
NCT06482944 — Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes · NA · recruiting
NCT07220746 — Understanding Cognitive-Academic Bidirectionality in Math Learning Disabilities · NA · recruiting
NCT06464497 — Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity · NA · recruiting
NCT05472961 — Eye Movements in Visual Search · NA · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00178919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University
Last refreshed: 24 May 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00178919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing